This study, called The PERSEVERE Study, is looking at a new way to treat high-risk pulmonary embolism (a blood clot in the lung). It compares the FlowTriever System, a device that removes blood clots, with the standard of care treatment. You might be able to join if you are at least 18 years old, have a blood clot in a main or lobar pulmonary artery, and have high-risk pulmonary embolism with right ventricle (RV) dysfunction (meaning the right side of your heart isn't pumping as well as it should). The study will measure how well these treatments work by looking at a combination of important health events, measured at hospital discharge or within 7 days. The current recruitment status is unclear.

Study design

This is a randomized controlled trial, meaning participants will be randomly assigned to receive either the FlowTriever System or standard of care. The study plans to enroll 200 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary outcomes are measured at the earlier of initial hospital discharge or 7 days after randomization.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.